INTRODUCTION
The extracellular calcium-sensing receptor (CaR) was cloned using mRNA from the bovine parathyroid gland in 1993 (1) . Since then, CaR expression has been described in other organs as well, including the thyroid, kidney (2,3), brain (3), intestine (3), testis, lung (except in mice) (4, 5) and pancreas (6) as well as in lens epithelial cells (7) , keratinocytes (8) , fibroblasts, osteoblasts (9,10) and osteoclasts (11) . The CaR is part of the GPCR family C, all of which have large extracellular domains responsible for ligand binding. Other class C GPCR include the metabotropic glutamate receptors, GABA B receptors, and a subset of pheromone, olfactory and taste receptors. ) and polyamines (e.g. spermine and neomycin) (12) . The CaR activates phospholipase C to produce inositol 1,4,5-trisphosphate (IP 3 ) which mobilizes intracellular calcium stores to increase intracellular calcium (13) . The CaR-mediated PI-PLC activation in parathryroid cells and HEK-hCaR has been reported to be pertussis toxin-insensitive and therefore G q/11 -mediated (14) . The CaR also has been reported to activate K + channels (15) and produce a pertussis toxin-sensitive (G i ) inhibition of agonist-stimulated cAMP accumulation in some cells (16) . These findings suggest that the CaR can couple to more than one population of G proteins.
The mitogen-activated protein kinase, MAP kinase, pathways have been described to regulate a number of cell processes such as cell growth, differentiation, apoptosis, oncogenetic transformation and enzyme activity (17) . These include the extracellular signal-regulated kinases (ERKs) that are stimulated by agonist binding to GPCR and tyrosine kinase growth factor receptors, as well as by mechanical stress in many cell types. The CaR has been shown to (10) and their respective cell lines (9) , parathyroid cells (19) , ovarian surface epithelia (20, 21) , and in a variety of cultured cell lines (19, (22) (23) (24) (25) (26) (27) (28) . Ca 2+ -stimulated activation of ERK1/2 by way of the CaR has been reported to occur via both pertussis toxin-sensitive (G i ) and -insensitive (G q/11 ) pathways (19) . It is possible that the mechanisms, and the physiologic outcomes, differ depending on whether CaR-stimulated ERK1/2 activation is mediated via G i or G q/11 .
The CaR specific agonist, NPS R-467, is a phenylalkylamine calcimimetic, which activates the CaR by allosterically increasing the affinity of the CaR for calcium (29, 30) . It has been determined that the dose-response curve for the ability of calcium to activate down-stream signaling cascades (intracellular calcium mobilization, ERK1/2 activation) in cells expressing the CaR is shifted to the left at least 10 fold in the presence of NPS R-467 (31 or dominant negative β-arrestin 2 using the Polyfect® Transfection Reagent (Qiagen, catalogue # 301105) according to the handbook directions. Forty-eight hours after transfection, the cells were stimulated with agonists, and ERK1/2 activation was determined as described above. To confirm positive expression of both forms of transfected dynamin, membranes from both wildtype and K44A transfected cells were harvested, subjected to SDS-PAGE and Western blot analyses using an antibody directed against dynamin (Transduction Laboratories, Lexington, KY; catalogue # D25520) and compared to untransfected control cells.
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Co-expression of PTX-resistant Gα i subunits -The cDNAs of individual pertussis-toxin
insensitive Gα i subunits were transiently co-expressed using the Polyfect® Transfection Reagent as described above. The cDNA constructs that have the C351I mutation render these subunits (Gα i1 , Gα i2 and Gα i3 ) insensitive to PTX treatment, as described previously (34) .
Immunofluorescence analysis and confocal microscopy -All steps were done at room Fig. 1A, and immunofluorescence, Fig. 1B ). The lack of ERK1/2 activation in HEK-293 cells not heterologously expressing the CaR (Fig. 1A) indicates that the ERK1/2 signaling in this cell line (19) is CaR-mediated. Interestingly, the time course of ERK1/2 activation was delayed when NPS R-467 was used to activate CaR when compared to activation by 4 mM Ca (Fig. 1B) , nor in the absence of added CaCl 2 (data not shown).
Lack of ERK1/2 desensitization in HEK-hCaR cells with the NPS R-467 agonist vs. Ca
2+ aloneConsistently, we observed that 4 mM Ca 2+ stimulated ERK1/2 was reduced at 60 minutes to a level slightly above baseline, and down to baseline by 4 hours (Fig. 2A) . In contrast, there was no significant desensitization to CaR stimulation of ERK1/2 phosphorylation when 1 µM NPS R-467 in the presence of 0.5 mM CaCl 2 were used as agonists, even as late as 240 minutes after addition of stimulus (Fig. 2B) . A densitometric analysis of the data obtained from four to six separate experiments comparing the 10 and 60 minute time points for ERK1/2 activation in figure 1B reveals that there is significant desensitization with the endogenous ligand, calcium, for the CaR, whereas there is no desensitization at 60 minutes with NPS R-467. The desensitization observed with 4 mM calcium undergoes rather rapid resensitization (Fig. 2C) . 
Blocking Receptor Internalization Inhibits CaR Agonist-mediated ERK1/2 Activation -
Numerous studies have shown that some GPCR require internalization to activate ERK1/2. To determine whether CaR endocytosis is required for ERK1/2 activation, we exploited several independent experimental strategies used to inhibit recruitment to clathrin-coated pits (pretreatment of concanavalin A, which prevents internalization of membrane-associated receptors by stabilizing the surface integrity due to tetravalent lectin contacts (35) with calcium channels. The functional efficacy of the concanavalin A treatment to block CaR endocytosis is seen in the confocal images in Fig. 3B , where the intracellular pool of CaR present at steady-state is no longer as prevalent, as well as in its ability to block EGF receptor-mediated ERK1/2 activation on the same blot (Fig. 3A) , as the ability of concanavalin A to block the tyrosine kinase receptor-mediated activation of ERK1/2 has been demonstrated in some systems (33, 36) . These findings suggest that CaR internalization is partially required for ERK1/2 activation and further suggest the possibility that like other GPCR, CaR activation of ERK1/2 by NPS-R467/CaCl 2 and the later wave of 4 mM Ca 2+ activation may involve receptor cross-talk with the receptor tyrosine kinase signaling pathway.
Dynamin is a 100 kDa GTPase that binds to clathrin-coated pits where it oligomerizes around the neck of the budding clathrin vesicles. A point mutant form of dynamin, K44A, is a dominant negative form of the wild-type in that it interferes with the regular dynamics of dynamin and thereby inhibits vesicular endocytosis (37) . Co-expression of dominant negative dynamin (K44A) was also explored as a tool to evaluate the dependence of internalization for agonist-elicited ERK1/2 activation. As seen in Fig. 4A , overexpression of dynamin K44A (as confirmed by Western blot analysis using an antibody against dynamin, bottom blot) did not eliminate 4 mM CaCl 2 -mediated ERK1/2 activation in HEK-hCaR. The ability of dynamin K44A to interfere with the normal internalization processes was confirmed by its ability to block EGF receptor-mediated ERK1/2 activation, as has been previously described by others (38, 39) , and argue against a need for EGF receptor signaling cross-talk to achieve CaR activation of ERK1/2. (The lack of total elimination of EGF receptor-mediated ERK1/2 activation can be attributed to the 70% transfection efficiency of this procedure (40)). When HEK-hCaR cells co- However, dominant negative β-arrestin 2 did block EGF-stimulated ERK1/2 activation. Lastly, as seen in Figure 4D , expression of K44A or dominant negative dynamin did not effect stimulation with NPS R-467 as late as 4 hours, time points at which the allosteric modulator has its most distinguishing effects.
The Pertussis Toxin-Sensitive Activation of ERK1/2 by CaR is restored by Gα i2, but not by Gα i1
or Gα i3 -Numerous GPCR mediate MAP kinase activation by coupling to the G i family of G proteins, and are therefore sensitive to pertussis toxin pretreatment. modulator, then this might afford a mechanism for the differences in the kinetics of ERK1/2 dephosphorylation and inactivation.
Resensitization of GPCR following short-term (seconds to minutes) desensitization has been shown to involve receptor recycling. Mechanisms which attenuate the GPCR's signaling events are crucial to the maintenance of their ability to respond to agonists over time. The ability of calcium-stimulated ERK1/2 phosphorylation to recover (resensitize) after desensitization ( Within the last decade, many reports have shown that GPCR internalization is necessary for ERK activation, including the α and β-adrenergic receptors (39), some muscarinic receptor subtypes (42), the opioid receptors (43) as well as others. Still other groups have shown that GPCR-mediated ERK activation can be internalization independent, including the α2-adrenergic receptors (32), some muscarinic receptors (44), the B2 bradykinin receptor (45), some opioid receptor subtypes (46) and more. Our data provide evidence that CaR internalization is important for ERK1/2 activation, but occurs via a pathway that is dynamin-or arrestin-independent.
A possible explanation as to why only partial elimination of ERK1/2 activation with concanavalin A is observed in cells stimulated with 4 mM CaCl 2, but not with NPS-R467, is that (47) . Thus, the observed kinetics of calcium-stimulated ERK1/2 activation might represent "cross-talk" with another signaling partner, one which is resistant to general internalization inhibitors.
A lack of an apparent reliance on dynamin for agonist-induced ERK1/2 activation and yet a dependence on the ability of the receptor to undergo internalization may be related to the previously described association of CaR with caveolae. The work of Edward Brown and colleagues has shown the CaR to reside in caveolin-rich membrane domains of parathyroid cells, the localization of which might dictate some of the signaling pathways this GPCR couples to, particularly since CaR in the parathyroid caveolae colocalizes with G q/11 (48) . Furthermore, during the course of our studies, they showed that the carboxy tail of CaR binds to filamin-A (a potential scaffolding protein which also binds to caveolin-1 as well as several players of the MAP kinase family), and that disruption of the CaR-filamin-A interaction in HEK-293 cells expressing CaR greatly attenuates CaR-mediated ERK1/2 activation with calcium (49). This latter study suggests, albeit indirectly, that a component of calcium-induced CaR-mediated ERK1/2 activation takes place in caveolae. However, it may not be mutually exclusive from a dynamin or clathrin-coated pit-dependent mechanism, especially since a component of the ERK1/2 activation is G i -dependent and also in light of our observed different kinetics of activation (Fig. 2) , depending on the ligand being used. activation. By using a transient expression system for PTX-insensitive Gα i subunits, we found that Gα i2 , but not Gα i1 or Gα i3, was responsible for the G i -mediated ERK1/2 activation since only the Gα i2 C351I was able to restore PTX-attenuated CaR-mediated ERK1/2 phosphorylation (Fig. 6) . In an elegant series of experiments in 1995, Bourne and colleagues used this exact strategy in CHO cells, where they demonstrated that the Gα i2 subunit is responsible for activating the MAP kinase cascade in these cells as well (50) . This novel finding may prove to be a very useful tool in the future for selectively activating one part of the signaling network of CaR-mediated events over another.
Our data provide strong evidence for two different ERK1/2 activation pathways in response to the CaR, depending on whether calcium or the calcimimetic NPS R-467 are used.
Since there is mounting evidence that the CaR plays a role in the regulation of cell proliferation (51) (52) (53) , the pharmacologically distinct mechanisms of CaR-mediated ERK1/2 activation may represent cellular mechanisms to differentially regulate the temporal and spatial activity of MAP kinases, thereby determining the consequences of this GPCR stimulation with respect to transcriptional activation, cell proliferation and apoptosis. A. 
